Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.40 | -$0.40 | -$0.40 |
Q2 2024 | 1 | -$0.36 | -$0.36 | -$0.36 |
Q3 2024 | 3 | -$0.32 | -$0.20 | -$0.25 |
Q1 2025 | 2 | -$0.28 | -$0.23 | -$0.26 |
Q2 2025 | 1 | -$0.28 | -$0.28 | -$0.28 |
Q3 2025 | 1 | -$0.29 | -$0.29 | -$0.29 |
Q4 2025 | 1 | -$0.31 | -$0.31 | -$0.31 |
Q1 2026 | 1 | -$0.48 | -$0.48 | -$0.48 |
Q2 2026 | 1 | -$0.54 | -$0.54 | -$0.54 |
Q3 2026 | 1 | -$0.55 | -$0.55 | -$0.55 |
Q4 2026 | 1 | -$0.55 | -$0.55 | -$0.55 |
Tempest Therapeutics, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.41 earnings per share for the quarter, missing analysts' consensus estimates of $-0.37 by $0.04. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Tempest Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.91 diluted earnings per share) and currently has a price-to-earnings ratio of -0.62. Tempest Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | -$0.37 | -$0.41 | -0.04 | $0 | $0 |
08/08/2024 | Q2 2024 | -$0.47 | -$0.42 | 0.05 | $0 | $0 |
05/09/2024 | Q1 2024 | -$0.44 | -$0.36 | 0.08 | $0 | |
03/19/2024 | Q4 2023 | -$0.38 | -$0.35 | 0.03 | $0 | |
11/08/2023 | Q3 2023 | -$0.55 | -$0.48 | 0.07 | $0 | |
08/10/2023 | Q2 2023 | -$0.58 | -$0.54 | 0.04 | $0 | |
05/10/2023 | Q1 2023 | -$0.66 | -$0.58 | 0.08 | $0 | |
03/22/2023 | Q4 2022 | -$0.95 | $0 | |||
11/08/2022 | Q3 2022 | -$0.76 | -$0.67 | 0.09 | $0 | |
08/15/2022 | Q2 2022 | -$0.92 | -$0.83 | 0.09 | $0 | |
05/13/2022 | Q1 2022 | -$1.12 | -$1.23 | -0.11 | $0 | |
03/31/2022 | Q4 2021 | -$1.16 | $0 | |||
11/10/2021 | Q3 2021 | -$1.05 | -$1.21 | -0.16 | $0 | |
08/12/2021 | Q2 2021 | -$0.88 | -$7.63 | -6.75 | $0 | |
05/13/2021 | Q1 2021 | -$5.25 | -$0.81 | 4.44 | $0 | |
03/29/2021 | Q4 2020 | -$4.67 | $0 | |||
11/09/2020 | Q3 2020 | -$6.90 | -$0.82 | 6.08 | $0 | |
08/10/2020 | Q2 2020 | -$8.20 | -$0.79 | 7.41 | $0 | |
05/08/2020 | Q1 2020 | -$10.00 | -$4.67 | 5.33 | $0 | |
03/11/2020 | Q4 2019 | -$13.72 | $0 |
Tempest Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based off last year's report dates.
The conference call for Tempest Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Tempest Therapeutics, Inc.'s latest earnings report can be read online.
Tempest Therapeutics, Inc. (:TPST) has a recorded net income of $0. Tempest Therapeutics, Inc. has generated $-1.91 earnings per share over the last four quarters.
Tempest Therapeutics, Inc. (:TPST) has a price-to-earnings ratio of -0.62 and price/earnings-to-growth ratio is -0.14.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED